Laekna (HKSE:02105) FCF Yield % : -13.51 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Laekna's Trailing 12-Month Free Cash Flow is HK$-354.20 Mil, and Market Cap is HK$2,621.47 Mil. Therefore, Laekna's FCF Yield % for today is -13.51%.

The historical rank and industry rank for Laekna's FCF Yield % or its related term are showing as below:

HKSE:02105' s FCF Yield % Range Over the Past 10 Years
Min: -28.55 Med: 0 Max: 0
Current: -13.51

HKSE:02105's FCF Yield % is ranked better than
51.96% of 1553 companies
in the Biotechnology industry
Industry Median: -14.22 vs HKSE:02105: -13.51

Laekna's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Laekna FCF Yield % Historical Data

The historical data trend for Laekna's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna FCF Yield % Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

-4.18

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	-	-	-	-5.18	-

Competitive Comparison of Laekna's FCF Yield %

For the Biotechnology subindustry, Laekna's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laekna's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Laekna's FCF Yield % falls into.

Laekna FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Laekna's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-324.76	/	7762.99
	=	-4.18%

Laekna's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	2	/	7762.99
	=	0.00%

Laekna FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Laekna FCF Yield % Related Terms

Thank you for viewing the detailed overview of Laekna's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna (HKSE:02105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Gp Healthcare Capital, Inc.	2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Liu Zeng	2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Liu Ying	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines